We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.30 | -0.20% | 146.52 | 147.175 | 145.95 | 146.70 | 1,760,275 | 17:09:07 |
From Apr 2019 to Apr 2024
By Stephen Nakrosis
The Janssen Pharmaceutical Companies of Johnson & Johnson presented long-term data from its Phase 3 VOYAGE 1 clinical trial of Tremfya, a treatment for adult patients with moderate to severe plaque psoriasis.
The data, being presented at the 39th Fall Clinical Dermatology Conference, studied patients receiving Tremfya, or guselkumab, from a group initially randomized to Tremfya or to placebo with crossover to Tremfya at week 16. Janssen said 82% achieved at least a 90% improvement in the Psoriasis Area Severity Index.
At 204 weeks, patients receiving Tremfya continued to show maintained PASI 90 and an Investigator's Global Assessment score of cleared or minimal disease, the company said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 17, 2019 16:54 ET (20:54 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
